Shalby Targets 20% EBITDA Margin by FY27

Shalby Limited — Q1 FY2027 (Earnings call held Aug 13, 2026)

1. Overall Tone of Management

Optimistic. Management highlights “healthy improvement across all key financial parameters,” expects “improved margin from here on,” and repeatedly expresses confidence in forward momentum (e.g., “confident to see EBITDA margin of upward to 20% on the whole year basis” and MedTech “confident to see the same level of growth in the coming quarters”).

2. Key Themes from Management Commentary

• Consolidated growth with margin pressure at the hospital level
• Revenue up 11.6% YoY to ₹338.6 cr, but EBITDA margin down to 14.5% (from 16%) and PBT margin down.
• Hospital operational improvement, but profitability lag
• Occupancy improved to 51% (excluding Shalby International: 54%), occupied beds up 9.8% YoY.
• Management attributes margin softness to doctor/specialty ramp-up timing and TPA renewals/bunker effects flowing in subsequent quarters.
• Shalby International (Gurgaon) turning point
• Gurgaon unit achieved EBITDA break-even for the first time since acquisition, described as “sustainable and a growing EBITDA.”
• Management targets occupancy ~30% from Q3/Q4 and PBT positive around Q3/Q4 end (within ~6–9 months).
• MedTech: strong top-line growth + improving profitability
• MedTech revenue ₹47 cr, +53% YoY; India MedTech strong (+98% YoY).
• “EBITDA positive” for MedTech for the fourth consecutive quarter; management emphasizes operating leverage and working-capital discipline.
• Mentions a very high growth narrative: “CAGR of 93%… confident to see the same level of growth.”
• Working capital/inventory focus
• Inventory “on an improving trend,” with expectation of ~30% improvement in inventory holding days.
• Selective investment + ROCE narrative
• Claims minimal incremental CAPEX going forward due to prior investments; expects ROCE improvement to industry range 11–13% in 1–2 years.

3. Q&A Analysis

Theme A: Hospital margins—sustainability and drivers

• Core question(s):
• Will hospital margins sustain or improve further? Any headwinds/one-offs?
• What caused standalone EBITDA margin decline despite better occupancy?
• Management response:
• Margin upside is expected from:
  • “bunkers… activated also in Quarter 1” with “more uptrend to come”
  • TPA renewals with potential 5%–7% revenue jump
  • Gurgaon EBITDA positive and expected better margins
  • Other units (Krishna, Mohali, Naroda) growing ~30% YoY
  • Underperformers (Surat, Indore) being addressed via doctor recruitment
• For margin pressure: described as temporary due to new doctors/specialties ramping and bunker/TPA effects flowing in subsequent quarters.
• Evasive/partial/strong elements:
• Strong confidence language, but still timing-dependent (“takes some time about a quarter or so”; effects “flow into subsequent quarter”).
• No quantified reconciliation of margin bridge; relies on qualitative drivers.

Theme B: MedTech profitability—why EBITDA weak at US front; path to double-digit margins

• Core question(s):
• MedTech revenue up strongly, but EBITDA is weak (US especially). What drives weak profitability?
• When can they expect sustainable double-digit EBITDA margins?
• Management response:
• Main driver: FX impact (USD/INR).
• Volume: India volumes up significantly; US volumes “predominantly stable.”
• Profit improvement initiatives:
  • Invest cash/inflow reduction of ~₹3 cr/month
  • Additional project expected by Q4 FY27 to reduce cash requirement by another ~₹3 cr/month
  • Regulatory/US FDA changes take 6–9 months to 1 year; “half progress already made,” remaining in next 6 months.
• Double-digit EBITDA margin expected “from there on” after initiatives complete.
• Evasive/partial/strong elements:
• Provides a timeline framework (half progress + next 6 months; Q4 implementation), but does not give a precise quarter for double-digit EBITDA.
• US profitability explanation leans heavily on FX and execution/regulatory lead times.

Theme C: Shalby International (Gurgaon) occupancy and breakeven timeline

• Core question(s):
• With Gurgaon EBITDA positive at low occupancy, what are occupancy and margin aspirations for FY27?
• When will Gurgaon reach PBT breakeven?
• Management response:
• Occupancy target: ~30% from Q3 or Q4 onwards
• PBT positive: “Quarter 4 or near Quarter 3 end”, within 6–9 months
• Notes: already EBITDA positive (7% EBITDA) and specialties deployed; some effects expected in Q2/Q3.
• Strong elements:
• More specific than earlier calls (explicit occupancy and PBT timing).

Theme D: Tax rate, DTA recognition, and ETR trajectory

• Core question(s):
• Why deferred tax not recognized; when will DTA be recognized?
• What tax rate should be used for FY27?
• Management response:
• Hospital segment: DTA recognized “wherever required.”
• US MedTech: conservative approach—not recognizing DTA currently; will reconsider if profitability improves.
• FY27 tax: hospital moved to new scheme; management cites ~26% hospital tax and group ETR moderation (ETR 47% vs 66% YoY in Q1).
• Evasive/partial/strong elements:
• DTA timing remains conditional (“as soon we see profitability improving…”).

Theme E: Debt/rating and cash flow discipline

• Core question(s):
• ICRA downgrade drivers and how they manage debt profile with new working capital facility.
• Debt trajectory and whether net debt will rise.
• Management response:
• Rating: downgrade procedural assessment; outlook improved to stable, but could be re-evaluated.
• Working capital facility: replacement, not increase; ~30 bps lower cost.
• Net debt: expects stable or reducing trend; “do not estimate net debt to go higher.”
• Strong elements:
• Clear clarification that the Kotak facility is not incremental debt.

Theme F: Mumbai expansion status and CAPEX

• Core question(s):
• Progress on Mumbai expansion (trust/trustees alignment).
• Expected cash CAPEX outlay and how they balance with ROCE goals.
• Management response:
• Discussions with trustees ongoing; once alignment happens, approval/review by trust office.
• CAPEX: no number given; says greenfield project would be assessed differently; expects no further hospital/MedTech debt infusion.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Hospital EBITDA margin (FY27): “upward to 20% on the whole year basis”
• Gurgaon occupancy (FY27): “touch 30%… from Quarter 3 or Quarter 4 onwards”
• Gurgaon PBT positive: “Quarter 4 or near Quarter 3 end” (within 6–9 months)
• MedTech inventory holding days: expect ~30% improvement
• ROCE target: improve to industry standard 11–13% in 1–2 years
• MedTech cash requirement reduction: initiatives reduce cash requirement by ~₹3 cr/month, and another ~₹3 cr/month after Q4 implementation

Implicit signals (qualitative)

• Hospital margin improvement is temporary-lag driven (doctor ramp-up; bunker/TPA effects “flow” later).
• MedTech double-digit EBITDA margin is execution/regulatory dependent (US FDA timelines; “half progress already made”).
• CAPEX discipline: management implies minimal incremental CAPEX because prior investments already made (CAPEX-heavy FY26; “minimal CAPEX since we have already invested that”).

5. Standout Statements (direct / high-signal)

• Hospital margin upside drivers: “bunkers… activated also in the Quarter 1 but we see the more uptrend to come in the subsequent quarter”
• TPA renewals upside: “renewal… holds a potential of 5% to 7% jump on to our revenue”
• Gurgaon milestone: “Gurgaon unit has achieved its EBITDA break-even for the first time since the acquisition… “sustainable and a growing EBITDA”
• Gurgaon timeline: “occupancy level to touch 30%… from Quarter 3 or Quarter 4 onwards” and “Quarter 4 or near Quarter 3 end… PBT positive”
• MedTech profitability narrative: “EBITDA has been posted positive… fourth consecutive quarter”
• Double-digit EBITDA path (timing-dependent): US/regulatory changes take “6 to 9 months or one year… half of the progress is already made”
• ROCE credibility attempt: “we would expect that to fall… within industry standard from 1 to 2 years… 11% to 13%”
• Debt clarification: Kotak facility is “not a new fresh debt… just a replacement… 30 basis points lower”

6. Red Flags / Positive Signals

Red flags
– Margin guidance is conditional on execution timing (doctor ramp-up, TPA renewals, bunker activation effects “flow” later).
– MedTech US profitability explanation leans on FX and regulatory lead times; double-digit EBITDA timing remains somewhat open-ended.
– ROCE target vs current reality: management admits group ROCE is ~7% and standalone ~9.5%, yet expects industry range in 1–2 years—ambitious given ongoing margin volatility.
– Deferred tax/DTA remains conservative for US MedTech; could mask earnings power until profitability is sustained.

Positive signals
– Operational KPIs improving in hospitals: occupancy, occupied beds, ARPOB trend (though ARPOB slightly down YoY in Q1).
– Gurgaon turning point: EBITDA break-even achieved.
– MedTech: consistent EBITDA positivity (fourth consecutive quarter) and strong revenue growth.
– Working capital focus: inventory holding days improvement target and cash discipline initiatives.

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current (Q1 FY27): More confident/forward-looking with clearer milestones (Gurgaon occupancy ~30%, PBT positive by Q3/Q4 end; hospital EBITDA margin “upward to 20%”).
• Prior (Q4 FY26 & Q3 FY26): Tone was also constructive, but more about “turnaround/inflection” and less about specific occupancy/PBT timing.
• Shift classification: More Optimistic
• Management now asserts “EBITDA break-even… sustainable” for Gurgaon and provides more concrete FY27 targets.

b. Tracking Past Commitments vs Outcomes

• Gurgaon EBITDA breakeven timing
• Past (Q3 FY26): Management said Gurgaon “likely to be EBITDA positive… about 2 quarters ago” but there was a delay due to “management issues” and NABH timing.
• Current (Q1 FY27): Gurgaon achieved EBITDA break-even for the first time since acquisition.
• Assessment: ✅ Delivered (breakeven now achieved, though earlier “2 quarters ago” phrasing suggests delay).
• MedTech profitability turnaround
• Past (Q3 FY26): MedTech consolidated EBITDA turned positive (already described as turnaround).
• Current (Q1 FY27): “fourth consecutive quarter” of positive EBITDA.
• Assessment: ✅ Delivered / Sustained (improving consistency).
• Hospital margin normalization
• Past (Q3 FY26 / Q4 FY26): Repeated expectation of margin recovery as doctors/specialties and bunker/diagnostics ramp.
• Current: Margin still down YoY in Q1 (EBITDA margin 14.5% vs 16%), but management says it’s temporary and expects FY27 EBITDA margin up to 20%.
• Assessment: ⏳ Partially delivered / still in progress (improvement narrative continues, but Q1 shows margin compression).

c. Narrative Shifts

• Hospital: From “insurance disruptions/doctor attrition and ramp-up” (Q3 FY26) to “bunkers + TPA renewals + doctor ramp timing” (Q1 FY27). The story is now more mechanistic (specific levers) and less about external disruptions.
• Gurgaon: Now framed as a sustained EBITDA growth story rather than a delayed turnaround.
• MedTech: Shift from “turnaround/inflection point” (Q3/Q4 FY26) to “scalable diversified platform” with explicit cash/inventory discipline and regulatory execution timelines.

d. Consistency & Credibility Signals

• Credibility: Medium
• Positives: Gurgaon breakeven claim appears to have materialized; MedTech EBITDA positivity is consistent.
• Concerns: repeated reliance on “next quarter / subsequent quarter” for margin effects; some earlier “timing” language (e.g., Gurgaon EBITDA positive “2 quarters ago”) suggests slippage.
• Management provides more targets now, but still avoids detailed bridge/quant reconciliation.

e. Evolution of Key Themes

• Demand/Volumes (Hospitals): Improving occupancy/occupied beds in Q1 FY27; earlier calls discussed volume softness due to insurance negotiations and doctor churn.
• Margins (Hospitals): Still volatile—Q1 shows margin decline despite occupancy improvement; management attributes to ramp timing.
• MedTech: Direction Improving—repeated EBITDA positivity and strong revenue growth.
• Regulatory/Execution risk: Increasingly explicit in MedTech (US FDA timelines), while hospital risks are framed as operational ramp rather than external shocks.

f. Additional Insights (Cross-Period Intelligence)

• Risk build-up masked by optimism: Hospital EBITDA margin compression in Q1 FY27 despite “healthy improvement” suggests that operational improvements (occupancy) are not yet translating into profitability at the same pace—management is effectively asking investors to underwrite future margin conversion.
• Defensiveness in Q&A: Analysts pressed on “why bottom line deteriorated” (implants/MedTech) and “weak profitability at US front”; management responded with FX + accounting + timing, indicating sensitivity around profitability quality.
• ROCE narrative remains aspirational: Management now ties ROCE improvement to “minimal CAPEX” and prior investments, but current ROCE levels are far from target—credibility depends on sustained EBITDA conversion.